New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
08:15 EDTCVMCEL-SCI receives regulatory clearance to expand Phase III trial into Austria
CEL-SCI Corporation announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. Austria is the 14th country to participate in CEL-SCI’s trial which is already active in numerous clinics around the world. CEL-SCI’s Phase III trial is assessing the use of the company’s Multikine immunotherapy as a first line treatment for patients diagnosed with advanced primary head and neck cancer, prior to standard of care, which involves surgery, chemotherapy, and/or radiation therapy. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. Further expansion of CEL-SCI’s Phase III head and neck cancer trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers through by the end of 2015. Over 200 patients are already enrolled in, and being treated with Multikine.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
09:43 EDTCVMCEL-SCI to raise $1M in registered direct offering
Subscribe for More Information
09:22 EDTCVMCEL-SCI prices public offering of stock, warrants at 76c
CEL-SCI announced that it has priced a “best efforts” underwritten public offering of common stock and warrants at a combined price of 76c for aggregate gross proceeds of $6M. For every four shares sold, the company will issue to investors in the offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24. CEL-SCI intends to use the net proceeds of the offering for its Phase III clinical trial, other research and development, and general and administrative expenses. Laidlaw & Company is acting as the sole book-running manager and underwriter for the proposed offering.
09:15 EDTCVMOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Apple (AAPL), up 3%... Texas Instruments (TXN), up 2.3%... Harley Davidson (HOG), up 7%... Celanese (CE), up 4%... United Technologies (UTX), up 1.4%. ALSO HIGHER: Neonode (NEON), up 20% after signing technology development agreement with global tier-one printer OEM... Illumina (ILMN), up 10%, upgraded at Janney Capital following the company's better than expected Q3 earnings. DOWN AFTER EARNINGS: Coca-Cola (KO), down 5%... Chipotle (CMG), down 4.6%... Verizon (VZ), down 1%. ALSO LOWER: CEL-SCI (CVM), down 15.3% after announcing proposed offering of common stock, warrants... Omeros (OMER), down 12% after suspending Huntington's clinical trial with OMS824... Tesoro Logistics (TLLP), down 2.4% after 20M share secondary priced at $57.47... Rhino Resources (RNO), down 53%, downgraded to Underperform at Raymond James following the reduction in its quarterly cash dividend.
October 20, 2014
18:51 EDTCVMOn The Fly: After Hours Movers
Subscribe for More Information
16:57 EDTCVMCEL-SCI down 17.7% after announcing proposed offering of common stock, warrants
16:31 EDTCVMCEL-SCI announces proposed offering of common stock, warrants, no amount given
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use